Trials Sponsors Conditions Drugs Pricing

Conditions

Human Papillomavirus Vaccines

Outcome Measures

Primary Outcomes (5)

Feasibility - Recruitment
ratio of parents recruited to potential parents approached to participate in study
After enrollment completion, 6 months
Feasibility - Retention
ratio of parents completing post-intervention surveys to the number enrolled
Post intervention completion, 1 year
Feasibility - Intervention Delivery
ratio of parents receiving HPV message to the number enrolled
Two weeks after intervention begins
Feasibility - Intervention response
assessment of how often participants completed hesitancy questions across the intervention period
Two weeks after intervention completion
Feasibility - Intervention utility
Perceived ease of use, likeability, helpfulness, impact - Mobile App Rating Scale (1-inadequate, 2-poor, 3-acceptable, 4-good, and 5-excellent)
Two weeks after intervention completion

Secondary Outcomes (2)

Vaccine Intention
Immediately post-intervention (6 months)
Vaccine Confidence
Immediately post-intervention (6 months)

Study Arms (2)

Tailored Messaging

EXPERIMENTAL

Tailored messages based on parents' HPV vaccine hesitancy and perceived barriers to vaccination.

Behavioral: Tailored messages

Standard Messaging

ACTIVE COMPARATOR

Standard (untailored) messages about HPV vaccination reminder/recall.

Behavioral: Standard messages

Interventions

Tailored messagesBehavioral

Messages will be individually tailored to parents' responses to a baseline survey (child gender, vaccination status) and real-time responses to interactive prompts about vaccine hesitancy determinants with links to additional information (e.g., CDC, NJ Department of Health) and community resources to overcome barriers.

Tailored Messaging

Standard messagesBehavioral

Generic reminder/recall HPV vaccination messages.

Eligibility Criteria

Age18 Years - 80 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

parent or legal guardian of at least one child aged 9-13 years who has received 0 or 1 dose of HPV vaccine;
identify as Black or African American adult;

Sponsors & Collaborators

Rutgers, The State University of New Jersey
Otherlead
National Cancer Institute (NCI)
NIHcollaborator

Study Sites (1)

Rutgers

New Brunswick, New Jersey, 08901, United States

Study Officials

Racquel Kohler, PhD
Rutgers
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: TRIPLE
Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: HEALTH SERVICES RESEARCH
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant Professor

Study Record Dates

First Submitted

July 31, 2023

First Posted

August 21, 2023

Study Start

October 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

Study Stopped

HPV Vaccine Confident Families

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (5)

Secondary Outcomes (2)

Study Arms (2)

Tailored Messaging

Standard Messaging

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (5)

Secondary Outcomes (2)

Study Arms (2)

Tailored Messaging

Standard Messaging

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations